Shah K - Search Results

1

Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.

Henry E, Al-Janabi H, Brouwer W, Cullinan J, Engel L, Griffin S, Hulme C, Kingkaew P, Lloyd A, Payakachat N, Pennington B, Peña-Longobardo LM, Prosser LA, Shah K, Ungar WJ, Wilkinson T, Wittenberg E. Henry E, et al. Among authors: shah k. Pharmacoeconomics. 2024 Mar;42(3):343-362. doi: 10.1007/s40273-023-01321-3. Epub 2023 Dec 2. Pharmacoeconomics. 2024. PMID: 38041698 Free PMC article.

2

Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.

Hobbins A, Barry L, Kelleher D, Shah K, Devlin N, Goni JMR, O'Neill C. Hobbins A, et al. Among authors: shah k. Pharmacoeconomics. 2018 Nov;36(11):1345-1353. doi: 10.1007/s40273-018-0690-x. Pharmacoeconomics. 2018. PMID: 30051267 Free PMC article. Clinical Trial.

3

Exploration of the Reasons Why Health State Valuation Differs for Children Compared With Adults: A Mixed Methods Approach.

Dewilde S, Janssen MF, Lloyd AJ, Shah K. Dewilde S, et al. Among authors: shah k. Value Health. 2022 Jul;25(7):1185-1195. doi: 10.1016/j.jval.2021.11.1377. Epub 2022 Feb 28. Value Health. 2022. PMID: 35232661 Free article.

4

EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes.

Oppe M, Rand-Hendriksen K, Shah K, Ramos-Goñi JM, Luo N. Oppe M, et al. Among authors: shah k. Pharmacoeconomics. 2016 Oct;34(10):993-1004. doi: 10.1007/s40273-016-0404-1. Pharmacoeconomics. 2016. PMID: 27084198 Free PMC article.

5

Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.

Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N. Mulhern B, et al. Among authors: shah k. Pharmacoeconomics. 2018 Jun;36(6):699-713. doi: 10.1007/s40273-018-0628-3. Pharmacoeconomics. 2018. PMID: 29476363 Free PMC article.

6

Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.

Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N. Mulhern B, et al. Among authors: shah k. Pharmacoeconomics. 2018 Jun;36(6):727. doi: 10.1007/s40273-018-0648-z. Pharmacoeconomics. 2018. PMID: 29679315 Free PMC article.

7

International Valuation Protocol for the EQ-5D-Y-3L.

Ramos-Goñi JM, Oppe M, Stolk E, Shah K, Kreimeier S, Rivero-Arias O, Devlin N. Ramos-Goñi JM, et al. Among authors: shah k. Pharmacoeconomics. 2020 Jul;38(7):653-663. doi: 10.1007/s40273-020-00909-3. Pharmacoeconomics. 2020. PMID: 32297224

8

Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?

Ramos-Goñi JM, Estévez-Carrillo A, Rivero-Arias O, Rowen D, Mott D, Shah K, Oppe M. Ramos-Goñi JM, et al. Among authors: shah k. Value Health. 2022 Jul;25(7):1196-1204. doi: 10.1016/j.jval.2022.03.001. Epub 2022 Apr 1. Value Health. 2022. PMID: 35379562 Free article.

9

Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L.

Mott DJ, Devlin NJ, Kreimeier S, Norman R, Shah KK, Rivero-Arias O. Mott DJ, et al. Among authors: shah kk. Pharmacoeconomics. 2022 Dec;40(Suppl 2):129-137. doi: 10.1007/s40273-022-01214-x. Epub 2022 Nov 18. Pharmacoeconomics. 2022. PMID: 36396877 Free PMC article.

10

Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?

Mulhern B, Shah K, Janssen MF, Longworth L, Ibbotson R. Mulhern B, et al. Among authors: shah k. Value Health. 2016 Mar-Apr;19(2):210-7. doi: 10.1016/j.jval.2015.11.005. Epub 2016 Jan 8. Value Health. 2016. PMID: 27021755 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,371 results

Search Page